BETAGAN 0,5 % , collyre en solution en récipient unidose

( ARTG ) This product accepted for registration as 'currently supplied' at the time of commencement of the Act. Updated pregnancy risk category was approved as specified in the letter of 1 July 1992 from Dr B. Varma. Indicated treatment: 1. primary dysbetalipoprotinaemia (Type III hyperlipidaemia) that does not respond adequately to diet; and 2. adult patients with very high serum triglyceride levels (Types IV and V hyperlipidaemia) who present a risk of abdominal pain and who do not respond adequately to a determined dietary effort to control them. Patients with triglycerides in excess of 750mg per decilitre are likely to present such a risk. INDICATIONS AS AT 15 June 1994: Col is indicated for primary dysbetalipoproteinaemia (type III hyperlipidaemia) that does not respond adequately to diet. Col may also be considered for the treatment of adult patients with very high serum triglyceride levels (types IV and V hyperlipidaemia) who present a risk of abdominal pain and pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients with triglyceride levels in excess of 750mg per decilitre are likely to present such risk